Company Filing History:
1 out of 3,687 
1 out of 2,009 
1 out of 6 Years Active: 2024
Title: **James H. Segars: Innovator in Uterine Fibroids Treatment**
Introduction
James H. Segars is a distinguished inventor based in Baltimore, MD, known for his significant contributions to the treatment of uterine fibroids. With a focus on developing innovative methods to alleviate the symptoms associated with this condition, he has made remarkable advancements in the field of medical treatments.
Latest Patents
James H. Segars holds a patent for "Treatment of Uterine Fibroids Using Purified Collagenase." This innovative patent discloses compositions and methods for treating uterine fibroids in vivo. The disclosed methodologies aim to reduce symptoms related to uterine fibroids, including pain, bleeding, and infertility. The compositions contain collagenase in amounts effective for causing shrinkage and/or reducing the stiffness of uterine fibroids. This invention represents a significant step forward in the non-invasive treatment options available for patients suffering from uterine fibroids.
Career Highlights
Throughout his career, Segars has made noteworthy contributions while working at esteemed institutions such as The Johns Hopkins University and Duke University. His work in these prestigious environments has allowed him to collaborate with talented researchers and has significantly advanced the understanding and treatment of uterine fibroids.
Collaborations
During his career, James H. Segars has collaborated with several notable professionals, including Phyllis Carolyn Leppert and Thomas L. Wegman. These collaborations have fostered an environment of innovation and have enhanced the development of effective treatment solutions in gynecology.
Conclusion
James H. Segars continues to influence the medical field with his innovative approaches to treating uterine fibroids. His patented methods and collaborative efforts signal a promising future for patients seeking relief from the symptoms of uterine fibroids. As research and development in this area progress, Segars's contributions will undoubtedly play a critical role in improving patient outcomes.